



PTO/SB/08a (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/925,284-Conf. #2660		
		Filing Date	August 9, 2001		
		First Named Inventor	Daniel Hawiger		
		Art Unit	1644		
		Examiner Name	R.B. Schwadron		
Sheet	1	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,698,679	12-16-1997	Nemazee	
	A8*	US-5,869,057	02-09-1999	Rock	
	A9*	US-5,875,917	03-02-1999	Hart et al.	
	A10*	US-5,922,845	07-13-1999	Deo et al.	
	A11*	US-6,080,409	06-27-2000	Laus et al.	
	A12*	US-6,277,959	08-21-2001	Valladeau et al.	
	A13*	US-6,340,569	01-22-2002	Ball et al.	
	A14*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A15*	US-20020187131-A1	12-12-2002	Hawiger et al.	
	A16*	US-6,756,478-A1	06-29-2004	Valladeau et al.	
	A17*	US-20040001853-A1	01-01-2004	George et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>2</sup> Number <sup>2</sup> Kind Code <sup>2</sup> (if known)			
	B1	WO-86/01533-A1	03-13-1986	Celltech Limited	
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College	
	B3	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation	
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.	
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council	
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.	

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO. Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPW. \* Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No: EM 192 977 472 US Dated: February 20, 2009

819033-1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b> Application Number 09/925,284-Conf. #2660 Filing Date August 9, 2001 First Named Inventor Daniel Hawiger Art Unit 1644 Examiner Name R.B. Schwadron Attorney Docket Number RUJ-001CNCPRCE2	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)					
Sheet	3	of	12		

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY		
B13	WO-99/02562-A1	01-21-1999	Schering Corporation		
B14	WO-99/16455-A1	04-08-1999	The Austin Research Institute		
B15	WO-99/24554-A2	05-20-1999	University of Pittsburgh		
B16	WO-99/47673-A2	09-23-1999	Schering Corporation		
B17	WO-99/55369-A1	11-04-1999	Smithkline Beecham Corporation		
B18	WO-99/58678-A2	11-18-1999	Micromet GmbH		

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with a single asterisk (\*) next to the Cite No. are not supplied under 37 CFR 1.98(a)(2)(iii) because that application was filed after year 2003 or 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). See X-Kind codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 609. If the document is published by WIPO, the year of publication must precede the year of the reign of the Emperor must follow the document, by the two-letter code (WIPO Standard ST.3). Japanese documents must include the appropriate symbols as indicated on the document under WIPO Standard ST.16. If the document is not the patent document, \* Kind Code: The kind of document must be indicated on the document under WIPO Standard ST.16. If possible, \* Applicant is to place a check mark here if English language translation is attached.

Application Number	09/925,284-Conf. #2660
Filing Date	August 9, 2001
First Named Inventor	Daniel Hawiger
Art Unit	1644
Examiner Name	R.B. Schwadron
Attorney Docket Number	RUJ-001CNCPRCE2

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	MM-DD-YYYY			
	B19	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		
	B20	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		
	B21	WO-00/18803-A2	04-06-2000	Schering Corporation		
	B22	WO-00/63251-A1	10-26-2000	Katholieke Universiteit Nijmegen		
	B23	WO-01/25492-A1	04-12-2001	Biosite Diagnostics Inc. et al.		
	B24	WO-01/85798-A2	11-15-2001	Medarex, Inc.		

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and "not considered." Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) not cited to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that citation was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional) \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) and MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	09/925,284-Conf. #2660	
			Filing Date	August 9, 2001	
			First Named Inventor	Daniel Hawiger	
			Art Unit	1644	
			Examiner Name	R.B. Schwadron	
Sheet	6	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," <i>Vaccine</i> , Vol. 18:3174-3184 (2000)		
	C2	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)		
	C3	Berlyn, Kathleen A. et al, "Generation of CD4 <sup>+</sup> and CD8 <sup>+</sup> T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)		
	C4	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," <i>Science</i> , Vol. 242(4877):423-426 (1988)		
	C5	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," <i>Science</i> , Vol. 229:81-83 (1985)		
	C6	Casset, Florence et al., "A peptide mimetic of an anti-CD4 monoclonal antibody in rational design," <i>Biochemical and Biophysical Research Communications</i> , Vol. 307:198-205 (2003)		

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	09/925,284-Conf. #2660	
			Filing Date	August 9, 2001	
			First Named Inventor	Daniel Hawiger	
			Art Unit	1644	
			Examiner Name	R.B. Schwadron	
Sheet	7	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C7	Chen, Yvonne et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> , Vol. 293:865-881 (1999)		
	C8	Chien, Nadine C. et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)		
	C9	Cox, John C. et al., "Adjuvants - a classification and review of their modes of action," <i>Vaccine</i> , Vol. 15(3):248-256 (1997)		
	C10	De Pascalis, Roberto et al., "Grafting of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <i>The Journal of Immunology</i> , Vol. 169:3076-3084 (2002)		
	C11	Frlata, Davor et al., "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)		
	C12	Galfre, G. et al., "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , Vol. 266(7):550-552 (1977)		

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> CITE NO.: Those document(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	09/925,284-Conf. #2660	
			Filing Date	August 9, 2001	
			First Named Inventor	Daniel Hawiger	
			Art Unit	1644	
			Examiner Name	R.B. Schwadron	
Sheet	8	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C13	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)		
	C14	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab') <sub>2</sub> Antibody Containing Thioether-Linked Fab'γ Fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367-2375 (1987)		
	C15	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)		
	C16	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)		
	C17	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCGβ Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, 2nd ed., pg. 167 (2003)		
	C18	Janeway, Charles A. Jr. et al., "Localized regions of hypervariable sequence form the antigen-binding site," <i>Immunobiology</i> , 6 <sup>th</sup> Edition, Garland Science, Chpt. 3, pgs. 110-112 (2004)		
Examiner Signature	/Ronald Schwadron/			Date Considered 05/19/2010

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/925,284-Conf. #2660
		Filing Date	August 9, 2001
		First Named Inventor	Daniel Hawiger
		Art Unit	1644
		Examiner Name	R.B. Schwadron
Sheet	9	of	12
		Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C19	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)	
	C20	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)	
	C21	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)	
	C22	Lamminmäki, Urpo et al., "Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol," <i>The Journal of Biological Chemistry</i> , Vol. 276(39):36687-36694 (2001)	
	C23	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)	
	C24	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368:856-859 (1994)	
	C25	MacCallum, Robert M. et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography," <i>J. Mol. Biol.</i> , Vol. 262:732-745 (1996)	

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/IPTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/925,284-Conf. #2660		
		Filing Date	August 9, 2001		
		First Named Inventor	Daniel Hawiger		
		Art Unit	1644		
		Examiner Name	R.B. Schwadron		
Sheet	10	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C26	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fc $\alpha$ Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 148(6):1764-1770 (1992)	
	C27	Noorman, Femke et al, "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)	
	C28	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)	
	C29	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt.</i> , Vol. 78:118-132 (1985)	
	C30	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
Examiner Signature	/Ronald Schwadron/		Date Considered
			05/19/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b> Application Number <b>09/925,284-Conf. #2660</b> Filing Date <b>August 9, 2001</b> First Named Inventor <b>Daniel Hawiger</b> Art Unit <b>1644</b> Examiner Name <b>R.B. Schwadron</b> Attorney Docket Number <b>RUJ-001CNCPRCE2</b>		
Sheet	11	of	12		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C31	Ramakrishna, Vanky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)		
	C32	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)		
	C33	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)		
	C34	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)		
	C35	Schjetne, Karoline W. et al., "Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors," <i>The Journal of Immunology</i> , Vol. 178:4169-4176 (2007)		
	C36	Taylor, Lisa D. et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , Vol. 20(23):6287-6295 (1992)		

Examiner Signature	<u>/Ronald Schwadron/</u>	Date Considered	05/19/2010
--------------------	---------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> CITE NO.: Those document(s) which are marked with an double asterisk ("\*\*") next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>3</sup>Applicant's unique citation designation number (optional). <sup>4</sup>Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/925,284-Conf. #2660
		Filing Date	August 9, 2001
		First Named Inventor	Daniel Hawiger
		Art Unit	1644
		Examiner Name	R.B. Schwadron
Sheet	12	of	12
		Attorney Docket Number	RUJ-001CNCPRCE2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C37	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor- $\alpha$ Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C38	Tjoa, Benjamin A. et al, "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
	C39	Tuting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- $\alpha$ ," <i>The Journal of Immunotherapy</i> , Vol. 160:1139-1147 (1998)	
	C40	Wallace, Paul K. et al, "Exogenous antigen targeted to Fc $\gamma$ RI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)	
	C41	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	
	C42	Ward, E. Sally et al, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341:544-546 (1989)	
	C43	You, Zhaoyang et al, "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," <i>Cancer Research</i> , Vol. 61:3704-3711 (2001)	

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
--------------------	--------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> CITE NO.: Those document(s) which are marked with a double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.